Evidence map›Paper›PMID 33872399›Full record

ArticleClinical endocrinology2021

The clinical outcomes of COVID-19 infection in patients with a history of thyroid cancer: A nationwide study.

Mustafa Sahin, Cem Haymana, Ibrahim Demirci, Ilker Tasci, Emral Rıfat, Ugur Unluturk, Ilhan Satman, Tevfik Demir, Erman Cakal, Naim Ata and 8 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 1 country.

Mustafa SahinDepartment of Endocrinology and Metabolism, Ankara University, Ankara, Turkey.
Cem HaymanaDepartment of Endocrinology and Metabolism, Faculty of Medicine, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey.
Ibrahim DemirciDepartment of Endocrinology and Metabolism, Faculty of Medicine, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey.
Ilker TasciDepartment of Internal Medicine, Gulhane Faculty of Medicine and Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
Emral RıfatDepartment of Endocrinology and Metabolism, Ankara University, Ankara, Turkey.
Ugur UnluturkDepartment of Endocrinology and Metabolism, Faculty of Medicine, Hacettepe University, Ankara, Turkey.ORCID 0000-0002-5054-1396
Ilhan SatmanDepartment of Endocrinology and Metabolism, Faculty of Medicine, Istanbul University, Istanbul, Turkey.ORCID 0000-0001-8613-1797
Tevfik DemirDepartment of Endocrinology and Metabolism, Faculty of Medicine, Dokuz Eylul University, Ankara, Turkey.
Erman CakalDepartment of Endocrinology and Metabolism, Faculty of Medicine, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
Naim AtaDepartment of Strategy Development, Ministry of Health, Ankara, Turkey.
Derun ErtugrulDepartment of Endocrinology and Metabolism, Faculty of Medicine, University of Health Sciences, Kecioren Training and Research Hospital, Ankara, Turkey.ORCID 0000-0002-9199-9168
Serpil SalmanDepartment of Endocrinology and Metabolism, Medica Clinic, Istanbul, Turkey.
Ibrahim SahinDepartment of Endocrinology and Metabolism, Faculty of Medicine, Inonu University, Malatya, Turkey.
Selcuk DagdelenDepartment of Endocrinology and Metabolism, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Osman CelikMinistry of Health, Public Hospitals General Directorate, Republic of Turkey, Ankara, Turkey.
Murat CaglayanAnkara Provincial Health Directorate, Ankara, Turkey.
Aysegul AtmacaDepartment of Endocrinology and Metabolism, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey.
Alper SonmezDepartment of Endocrinology and Metabolism, Gulhane Faculty of Medicine and Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
Ministry of Health · TRSağlık Bilimleri Üniversitesi · TRAnkara University · TRGülhane Askerî Tıp Akademisi · TRHacettepe University · TRDokuz Eylül University · TRInonu University · TRIstanbul University · TROndokuz Mayıs University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are scarce published data in differentiated thyroid cancer patients about new coronavirus disease 2019 (COVID-19) disease outcomes and mortality. Here, we evaluated COVID-19 infection outcomes and mortality in thyroid cancer patients with COVID-19 infection. DESIGN AND

methodsWe included a cohort of patients with thyroid cancer with PCR-confirmed COVID-19 disease from 11 March to 30 May 2020 from the Turkish Ministry of Health database in our nationwide, retrospective study. We compared the mortality and morbidity of COVID patients with or without thyroid cancer. Univariate and multivariate analyses were used to assess the independent factors for mortality, length of hospital stay and intensive care unit (ICU) admission and mechanical ventilation. We also analysed the effect of radioiodine treatment on severity and death rate of COVID-19 disease.

resultsWe evaluated 388 COVID-19 patients with thyroid cancer [median age: 54 years, interquartile range (IQR) 18 years, males: 23%] and age and gender-matched 388 COVID-19 patients without thyroid cancer. Patients with thyroid cancer had a similar mortality ratio compared with the non-cancer group. Among patients with thyroid cancer, age, presence of diabetes mellitus, asthma/COPD, heart failure, chronic kidney disease, prior coronary artery disease, RAS blocker usage and low lymphocyte count were associated with mortality. Radioactive iodine (RAI) treatment and cumulative radioactive iodine dosage did not negatively affect the severity and mortality of COVID-19 disease in our patient group.

conclusionsOur study indicated that history of thyroid cancer did not have an increased risk of mortality or morbidity in COVID-19 disease. Besides, RAI therapy history and doses of radioactive iodine did not affect mortality or outcome.

Indexed as

COVID-19Thyroid NeoplasmsAdolescentHumansIodine RadioisotopesMaleRetrospective StudiesSARS-CoV-2Iodine RadioisotopesCOVID-19mortalityradioactive iodine therapythyroid cancer

Identifiers

PMID33872399
PMCPMC8251412
OpenAlexW3153169094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.